Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2016 Oct 1;2(10):1315-1316.
doi: 10.1001/jamaoncol.2016.1268.

ESR1 Mutations in Cell-Free DNA of Breast Cancer: Predictive "Tip of the Iceberg"

Suzanne A W Fuqua  1 , Yassine Rechoum  1 , Guowei Gu  1
Affiliations
Comment

ESR1 Mutations in Cell-Free DNA of Breast Cancer: Predictive "Tip of the Iceberg"

Suzanne A W Fuqua et al. JAMA Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. The New England Journal of Medicine. 2012;366:520–529. - PMC - PubMed
    1. Chandarlapaty S. ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer. JAMA Oncology 2016 - PMC - PubMed
    1. Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Science Translational Medicine. 2015;7:302ra133. - PubMed
    1. Gu G, Fuqua SA. ESR1 Mutations in Breast Cancer: Proof-of-Concept Challenges Clinical Action. Clinical Cancer Research. 2016;22:1034–1036. - PMC - PubMed
    1. Hortobagyi GN, Chen D, Piccart M, Rugo HS, Burris HA, 3rd, Pritchard KI, et al. Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of Clinical Oncology. 2016;34:419–426. - PMC - PubMed